

**\*\* For distribution in Europe only \*\***

May 1, 2023

NASDAQ | TSX: ACB

---

## **Aurora and Ethypharm Reaffirm their Commitment to Promote Access to Medical Cannabis for French Patients**

**Berlin - May 1, 2023** – Aurora Europe, a subsidiary of Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), and Ethypharm are pleased to announce, that they have once again been selected by the French General Directorate of Health (DGS) as exclusive suppliers of dried medical cannabis flower until the end of the French trial period. The trial has recently been extended until March 2024.

"We are delighted to have been selected once again to continue to supply high quality dried medical cannabis flower to the French pilot program. Driven by our purpose of opening the world to cannabis, Aurora continues to work hand-in-hand with government officials, physicians and pharmacists to reduce stigma and further develop medical markets throughout Europe," says Dr. Axel Gille, President of Aurora Europe.

Aurora and Ethypharm signed an agreement to serve the French pilot program, led by the National Agency for the Safety of Medicines and Health Products (ANSM), in October 2020, leveraging both parties' expertise. Under the terms of the exclusive partnership, Aurora supplies medical cannabis, as well as EU GMP (Good Manufacturing Practices) manufacturing and logistics support. Distribution and pharmacovigilance activities continue to be handled by Ethypharm Laboratories, Ethypharm's French sales subsidiary.

Within the framework of the extension of the trial, the DGS opened a call for tenders to supply medical cannabis in January 2023. In March, Aurora Europe and Ethypharm were selected to continue to provide medical cannabis produced according to European GMP standards to patients included in the study.

As committed partners, Ethypharm and Aurora Europe reaffirm their commitment to patients and healthcare professionals to improve the status and accessibility of medical cannabis in Europe.

"By combining our expertise in the Central Nervous System, more specifically in pain, and highly regulated medicines with Aurora's pharmaceutical grade medical cannabis products, we are proud to move forward with the French health authorities and health professionals in this experimentation which, we hope, will eventually show that the use of medical cannabis to relieve the pain of French patients is possible" says Denis Delval, President and CEO of Ethypharm.

### **About Aurora Europe**

Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies high-quality medical cannabis products to patients throughout Europe. Aurora is one of the largest authorised importers and distributors of medical

cannabis in the European Union & the UK with a production and distribution facility in Denmark with a maximum annual output of 10 tons. Aurora Deutschland, part of Aurora Europe GmbH, is one of three companies licensed to grow medicinal cannabis in Germany. Since May 2022, Aurora Produktions GmbH has been producing one ton of medicinal cannabis annually in Leuna, Saxony-Anhalt. Aurora's internal network of EU GMP facilities delivers high-quality, premium medical cannabis to patients worldwide. For more information please visit [www.auroramedicine.com](http://www.auroramedicine.com) or follow us on [www.linkedin.com/company/aurora-europe](https://www.linkedin.com/company/aurora-europe).

### **About Ethypharm**

Ethypharm is a European pharmaceutical company specializing in two areas: Central Nervous System and Hospital Injectable Drugs. Ethypharm markets its medicines directly in Europe and China, and has partners in North America and the Middle East. The Group employs more than 1,600 people, mainly based in Europe and China.

Ethypharm works closely with the authorities and healthcare professionals to ensure the appropriate use of and access to its medicines for the greatest number of people.

For more information about Ethypharm, visit our website <https://www.ethypharm.fr/> and follow us on LinkedIn.

### **Media contact:**

Anke Illigen | Senior Manager Communications Europe  
Aurora Europe GmbH | Wilmsdorfer Straße 98/99 | 10629 Berlin  
M +49 (0) 176 18000 423 | T +49 (0)30 9832 1601 0  
[anke.illigen@auroramedicine.com](mailto:anke.illigen@auroramedicine.com) | [www.auroramedicine.com](http://www.auroramedicine.com)

Avril PONNELLE | Group Communication Manager  
Ethypharm | 194 Bureaux de la Colline | 92213 Saint-Cloud Cedex - France  
M +33 6 3051 2527  
[presse@ethypharm.com](mailto:presse@ethypharm.com) | [www.ethypharm.com](http://www.ethypharm.com)